Replies to post #3869 on Dendreon Corp fka DNDNQ

[steveporsche]

So let me get this straight - Scher is on the Scientific Advisory Board for a ProQuest a healthcare VC firm, where Jay Moorin is partner, and Jay Moorin sits on the Board at Novacea. Novacea is running trials for the same pc target population as Provenge targets. Scher also Chairs one of these competing trials (Ascent-2). Novacea inks a deal three weeks after Provenge's complete response letter worth up to several hundred million dollars in precommercializion milestones. Novacea common stock is up 86% today because of this deal. How in the world could he be given a conflict of interest waiver and be afforded the opportunity to provide any advice whatsover to the FDA on the Provenge BLA?


http://www.proquestvc.com/investment_team_moorin.asp